Patient and clinical global impression of change ratings for narcolepsy overall from the end of the stable-dose period to the end of the double-blind randomized withdrawal period
| Ratings . | Placebo, n (%) . | LXB, n (%) . |
|---|---|---|
| PGIc* | 65 | 69 |
| Very much better | 1 (1.5) | 1 (1.4) |
| Much better | 1 (1.5) | 12 (17.4) |
| A little better | 3 (4.6) | 6 (8.7) |
| No change | 10 (15.4) | 39 (56.5) |
| A little worse | 21 (32.3) | 8 (11.6) |
| Much worse | 20 (30.8) | 2 (2.9) |
| Very much worse | 9 (13.8) | 1 (1.4) |
| p value† | <0.0001 | |
| CGIc‡ | 65 | 68 |
| Very much improved | 0 (0.0) | 1 (1.5) |
| Much improved | 0 (0.0) | 12 (17.6) |
| Minimally improved | 3 (4.6) | 9 (13.2) |
| No change | 11 (16.9) | 34 (50.0) |
| Minimally worse | 12 (18.5) | 8 (11.8) |
| Much worse | 28 (43.1) | 4 (5.9) |
| Very much worse | 11 (16.9) | 0 (0.0) |
| p value† | <0.0001 |
| Ratings . | Placebo, n (%) . | LXB, n (%) . |
|---|---|---|
| PGIc* | 65 | 69 |
| Very much better | 1 (1.5) | 1 (1.4) |
| Much better | 1 (1.5) | 12 (17.4) |
| A little better | 3 (4.6) | 6 (8.7) |
| No change | 10 (15.4) | 39 (56.5) |
| A little worse | 21 (32.3) | 8 (11.6) |
| Much worse | 20 (30.8) | 2 (2.9) |
| Very much worse | 9 (13.8) | 1 (1.4) |
| p value† | <0.0001 | |
| CGIc‡ | 65 | 68 |
| Very much improved | 0 (0.0) | 1 (1.5) |
| Much improved | 0 (0.0) | 12 (17.6) |
| Minimally improved | 3 (4.6) | 9 (13.2) |
| No change | 11 (16.9) | 34 (50.0) |
| Minimally worse | 12 (18.5) | 8 (11.8) |
| Much worse | 28 (43.1) | 4 (5.9) |
| Very much worse | 11 (16.9) | 0 (0.0) |
| p value† | <0.0001 |
CGIc, Clinical Global Impression of Change; LXB, lower-sodium oxybate; PGIc, Patient Global Impression of Change.
*Results are shown for participants with data for ≥1 PGIc survey.
†Cochran–Mantel–Haenszel row means score test; due to no adjustments for multiplicity (or multiple comparisons), the p values presented are nominal.
‡Results are shown for participants with data for ≥1 CGIc survey.
Patient and clinical global impression of change ratings for narcolepsy overall from the end of the stable-dose period to the end of the double-blind randomized withdrawal period
| Ratings . | Placebo, n (%) . | LXB, n (%) . |
|---|---|---|
| PGIc* | 65 | 69 |
| Very much better | 1 (1.5) | 1 (1.4) |
| Much better | 1 (1.5) | 12 (17.4) |
| A little better | 3 (4.6) | 6 (8.7) |
| No change | 10 (15.4) | 39 (56.5) |
| A little worse | 21 (32.3) | 8 (11.6) |
| Much worse | 20 (30.8) | 2 (2.9) |
| Very much worse | 9 (13.8) | 1 (1.4) |
| p value† | <0.0001 | |
| CGIc‡ | 65 | 68 |
| Very much improved | 0 (0.0) | 1 (1.5) |
| Much improved | 0 (0.0) | 12 (17.6) |
| Minimally improved | 3 (4.6) | 9 (13.2) |
| No change | 11 (16.9) | 34 (50.0) |
| Minimally worse | 12 (18.5) | 8 (11.8) |
| Much worse | 28 (43.1) | 4 (5.9) |
| Very much worse | 11 (16.9) | 0 (0.0) |
| p value† | <0.0001 |
| Ratings . | Placebo, n (%) . | LXB, n (%) . |
|---|---|---|
| PGIc* | 65 | 69 |
| Very much better | 1 (1.5) | 1 (1.4) |
| Much better | 1 (1.5) | 12 (17.4) |
| A little better | 3 (4.6) | 6 (8.7) |
| No change | 10 (15.4) | 39 (56.5) |
| A little worse | 21 (32.3) | 8 (11.6) |
| Much worse | 20 (30.8) | 2 (2.9) |
| Very much worse | 9 (13.8) | 1 (1.4) |
| p value† | <0.0001 | |
| CGIc‡ | 65 | 68 |
| Very much improved | 0 (0.0) | 1 (1.5) |
| Much improved | 0 (0.0) | 12 (17.6) |
| Minimally improved | 3 (4.6) | 9 (13.2) |
| No change | 11 (16.9) | 34 (50.0) |
| Minimally worse | 12 (18.5) | 8 (11.8) |
| Much worse | 28 (43.1) | 4 (5.9) |
| Very much worse | 11 (16.9) | 0 (0.0) |
| p value† | <0.0001 |
CGIc, Clinical Global Impression of Change; LXB, lower-sodium oxybate; PGIc, Patient Global Impression of Change.
*Results are shown for participants with data for ≥1 PGIc survey.
†Cochran–Mantel–Haenszel row means score test; due to no adjustments for multiplicity (or multiple comparisons), the p values presented are nominal.
‡Results are shown for participants with data for ≥1 CGIc survey.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
